Teleflex Incorporated

NYSE:TFX

Medical - Instruments & Supplies

Healthcare
$165.85 +0.83%

+$1.04 today

Market cap
$6.58B
Beta
0.82
P/E (TTM)
-5.5
EPS (TTM)
-$22.79
Dividend yield
1.08%
52W Low $100.18High $139.67

Volume 1.16M

Average 0.80M

TFX Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Teleflex IncorporatedNYSE: TFX

Cost of Revenue · Q2 FY2026 · quarter ended Jun 2026

Cost of revenue declines year over year

Q2 FY2026 cost of revenue of $238.63M fell 31.8% year over year, behind the -11.0% change in trailing-twelve-month cost of revenue. Sequentially, it fell 0.9% from the prior quarter. Over 3 fiscal years it compounded at -11.5% a year.

Context

  • Cost of revenue amounted to 43.8% of revenue in FY2025, down 0.4 pp from a year earlier.
  • Cost of revenue increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -31.8% toward the trailing-twelve-month pace of -11.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$238.63M-0.9% QoQ
Last fiscal yearDec 2025
$871.96M-35.2% YoY
LTMJun 2026
$1.2B-11.0% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-31.8%——
1 year-35.2%——
3-year CAGR-11.5%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
871.96M USD
Year-over-year change
-35.2%
4-year CAGR
-8.8%

Cost of Revenue vs competitors

How TFX compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -11.0% is the 9th highest of 10, against a peer median of +8.0%.
  • Cost of revenue amounts to 46.2% of revenue for TFX, versus a peer median of 17.9%.
TFX Competitors
Cost of Revenue for TFX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BLCOBausch + Lomb CorporationLTM Jun 2026$2.28B USD+8.0%+15.0%42.8%
TFXTeleflex IncorporatedLTM Jun 2026$1.2B USD-11.0%-11.5%46.2%
STVNStevanato Group S.p.A.LTM Jun 2026€865.62M EUR+5.0%+6.8%70.8%
MMSIMerit Medical Systems, Inc.LTM Sep 2026$815.11M USD+7.2%+7.2%50.6%
ALKSAlkermes plcLTM Sep 2026$300.12M USD+41.3%-3.4%17.1%
PTCTPTC Therapeutics, Inc.LTM Jun 2026$180.19M USD+250.5%+17.1%17.9%
CRSPCRISPR Therapeutics AGLTM Sep 2026$165.86M USD-3.5%+28.3%658.9%
TGTXTG Therapeutics, Inc.LTM Sep 2026$154.93M USD+98.5%+624.3%17.3%
KRYSKrystal Biotech, Inc.LTM Jun 2026$29.34M USD+23.1%—6.7%
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 2026$1.8M USD—-47.6%0.4%
PCVXVaxcyte, Inc.LTM Jun 2026$865K USD-82.7%——
Peer median (excluding TFX) —+8.0%+11.1%17.9%

Competitors are the stored peer set for TFX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.81B2.79B2.97B3.05B1.99B
Cost of Revenue1.26B1.26B1.33B1.34B871.96M
Gross Profit1.55B1.53B1.65B1.7B1.12B
Gross Margin55.2%54.9%55.4%55.9%56.2%
Research & Development130.84M153.82M154.35M161.67M144.78M
Selling, General & Admin860.09M863.75M929.87M995.27M720.17M
Operating Expenses921.51M1.03B1.14B1.55B864.95M
Depreciation & Amortization237.36M230.59M242.12M274.6M177.74M
EBITDA853.8M730.77M761.21M433.62M302.51M
EBITDA Margin30.4%26.2%25.6%14.2%15.2%
Operating Income628.1M499.73M506.31M151.01M255.8M
Operating Margin22.4%17.9%17.0%5.0%12.8%
Interest Income1.33M912K12.78M8.01M6.4M
Interest Expense56.97M54.26M85.08M83.54M100.22M
Other Income / Expenses(68.63M)(53.81M)(72.3M)(75.54M)(231.25M)
Income Before Tax559.47M445.92M434.01M75.48M24.55M
Pre-Tax Margin19.9%16.0%14.6%2.5%1.2%
Income Tax Expense74.35M83M76.44M5.32M(33.98M)
Net Income485.37M363.14M356.33M69.68M(905.64M)
Net Margin17.3%13.0%12.0%2.3%-45.4%
EPS (Basic)10.387.747.581.49(20.30)
EPS (Diluted)10.237.687.531.48(20.25)
Weighted Avg Shares46.77M46.9M46.98M46.84M44.62M
Weighted Avg Shares (Diluted)47.43M47.31M47.3M47.09M44.72M

Teleflex Incorporated

NYSE:TFX

Intrinsic Alpha fair value

Locked

Current Price

$165.85

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.